Follow on Google News News By Tag * Drug * Incontinence * Urinary * Clinical * Pipeline * Patient * Trial * Treatment * Oxybutynin * Papers * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Just Released: "Pipeline and Commercial Insight: Urinary Incontinence"Recently published research from Datamonitor, "Pipeline and Commercial Insight: Urinary Incontinence - Marketing investment and niche positioning are key strategies for success", is now available at Fast Market Research
Features and benefits * Sales forecasts of marketed brands, generics, and pipeline agents in seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) * In-depth clinical and commercial profiles of key marketed brands and late-stage pipeline agents with country-specific forecasts to 2019 * Patient potential analysis across the seven major markets including patient forecasts split by urinary incontinence type to 2019. * Review of the key unmet needs and opportunities in the market supported by key opinion leaders. * Analysis of current treatment approaches, patient acquisition, and key marketing strategies adopted by companies to drive drug uptake. Highlights Urinary incontinence affects over 83 million women across the seven major markets. Anticholinergics form the mainstay of drug treatment yet side effects of dry mouth and constipation often cause patients to discontinue their medication. As such, efficacious drugs with new modes of action and fewer side effects will be well received in the marketWhile competition in the anticholinergic class is fierce, there is an opportunity for companies with large commercial resources to develop the market further due to the high unmet need and the large patient population. As Pfizer turns its focus elsewhere, Astellas will become the leading company in the urinary incontinence market in 2019.Opportunities exist in targeting niche populations as the sales and marketing spend required to market products populations will be lower, allowing specialist companies to define and own a segment of the market with reduced competition. One such example is Allergan with Botox (botulinum toxin A) in development for neurogenic bladder. Your key questions answered * What key strategies were implemented by companies to drive urinary incontinence drug uptake and will these remain viable over the next decade? * What is the potential for novel therapies, such as Allergan's Botox and Astellas's mirabegron, in the competitive urinary incontinence market? * What will be the impact of key market events, such as patent expiries and new drug launches, on the future urinary incontinence market? * What will be the patient potential in urinary incontinence up to 2020 split by disease subtype? For more information or to purchase this report, go to: - http://www.fastmr.com/ Partial Table of Contents: Executive Summary Strategic scoping and focus Datamonitor insight into the urinary incontinence market Related reports VERVIEW Catalyst Summary EPIDEMIOLOGY Introduction Key findings Disease definition, classification and diagnosis criteria Risk factors Age Gender Pregnancy/Childbirth Race besity Hysterectomy Smoking Co-morbidities Global variation and temporal trends Epidemiologic forecasting of urinary incontinence methodology Sources of epidemiologic data Description of methods Results Urinary incontinence Stress urinary incontinence Urge urinary incontinence Mixed urinary incontinence ther urinary incontinence Discussion Strengths of Datamonitor's epidemiologic projections Conclusions TREATMENT OVERVIEW Key findings verview of urinary incontinence Normal bladder function Urinary incontinence Treatment overview Behavioral techniques Physical therapy Pharmacological treatment Medical devices Non surgical procedures Surgery Unmet need in urinary incontinence Need for alternative mechanisms of action Need for improved compliance Need for improved efficacy over side effects profile Need for medical treatment for stress urinary incontinence Need for on-demand use drugs Target product profile versus current level of attainment MARKET OVERVIEW Key findings Market definition for this report Seven major markets Current and future market overview US Current and future market assessment Japan Current and future market assessment Five major European markets (5EU) Current and future market assessment France Current and future market assessment Germany Current and future market assessment Italy Current and future market assessment Spain Current and future market assessment UK Current and future market assessment Rest of the world snapshot Current market assessment BRAND DYNAMICS Key findings verview of competitive landscape Me too drugs battle for market share Patient acquisition process Introduction Patient care path Points of influence in the patient care path Drivers of brand choice US formulary tier status for leading brands Trends in marketing strategies Marketing strategy for leading brands Patient support groups Sponsorship/ Direct-to-consumer advertising Detrol/Detrol LA (tolterodine tartrate; Pfizer) - Comparator therapy Drug profile SWOT analysis Product positioning Brand forecast to 2019 Toviaz (fesoterodine fumarate; Pfizer) Drug profile SWOT analysis Product positioning Brand forecast to 2019 Vesicare (solifenacin succinate; Astellas/GlaxoSmithKline) Drug profile SWOT analysis Product positioning Brand forecast to 2019 Enablex (darifenacin hydrobromide; Drug profile SWOT analysis Product positioning Brand forecast to 2019 Sanctura/Sanctura XR (trospium chloride; Endo Pharmaceuticals/ Drug profile SWOT analysis Product positioning Brand forecast to 2019 Full Table of Contents is available at: -- http://www.fastmr.com/ About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number